scispace - formally typeset
M

Mila E. McCurrach

Researcher at Cold Spring Harbor Laboratory

Publications -  20
Citations -  10282

Mila E. McCurrach is an academic researcher from Cold Spring Harbor Laboratory. The author has contributed to research in topics: Apoptosis & Retinoblastoma protein. The author has an hindex of 17, co-authored 20 publications receiving 9805 citations.

Papers
More filters
Journal ArticleDOI

Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a

TL;DR: It is shown that expression of oncogenic ras in primary human or rodent cells results in a permanent G1 arrest, and that the onset of cellular senescence does not simply reflect the accumulation of cell divisions, but can be prematurely activated in response to an onCogenic stimulus.
Journal ArticleDOI

FADD: Essential for Embryo Development and Signaling from Some, But Not All, Inducers of Apoptosis

TL;DR: CD95, tumor necrosis factor receptor type 1 (TNFR-1), and death receptor 3 (DR3) did not induce apoptosis in FADD-deficient embryonic fibroblasts, whereas DR4, oncogenes E1A and c-myc, and chemotherapeutic agent adriamycin did.
Journal ArticleDOI

Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes

TL;DR: Examination of the role of CPP32 in apoptosis using mice, embryonic stem cells, and mouse embryonic fibroblasts deficient for the caspase indicates that CPP 32 is an essential component in apoptotic events that is remarkably system- and stimulus-dependent.
Journal ArticleDOI

E1A signaling to p53 involves the p19(ARF) tumor suppressor.

TL;DR: Reintroduction of p19(ARF) functions as part of a p53-dependent failsafe mechanism to counter uncontrolled proliferation and may contribute to E1A's ability to enhance radio- and chemosensitivity.
Journal ArticleDOI

INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53

TL;DR: In conclusion, the Emu-myc transgenic lymphoma model generated genetically defined tumors with mutations in the INK4a/ARF, Rb, or p53 genes, which led to aggressive tumors by disrupting overlapping tumor suppressor functions.